Molecular Partners AG (SWX:MOLN)
3.090
-0.030 (-0.96%)
Jun 19, 2026, 5:30 PM CET
Molecular Partners AG Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Molecular Partners AG stock has a consensus rating of "Buy" and an average price target of CHF 9.00. The average 1-year stock price forecast is 191.26% higher than the current stock price, while the lowest is CHF 3.00 (-2.91%) and the highest is CHF 15.00 (+385.44%).
Price Target: CHF 9.00 (+191.26%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 16, 2026.
Analyst Ratings
The average analyst rating for Molecular Partners AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains CHF 15.00 | Buy | Maintains | CHF 15.00 | +385.44% | Mar 16, 2026 |
Financial Forecast
Revenue This Year
5.58M
Revenue Next Year
30.69M
from 5.58M
Increased by 450.00%
EPS This Year
-1.03
from -1.65
EPS Next Year
0.23
from -1.03
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CHF.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 22.3M | ||
| Avg | 5.6M | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 2,100.0% | |
| Avg | 450.0% | |
| Low | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.65 | ||
| Avg | -1.03 | ||
| Low | -1.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |